Linoladiol-H N

Estradiol hemihydrate and prednisolone sesquihydrate, the active ingredients in Linoladiol-H N, are an estrogen and a corticosteroid presented as a topical formulation for skin application. It treats estrogen deficiency and inflammatory skin conditions in adult women.

GNH USA supplies Linoladiol-H N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linoladiol-H N combines an estrogen and a corticosteroid and is used in therapeutic areas that involve hormonal regulation and inflammation.

Menopausal estrogen deficiency: provides localized estrogen to relieve urogenital atrophy and dryness. Inflammatory dermatoses: reduces redness, swelling and itching associated with eczema or contact dermatitis. Post‑menopausal skin aging: improves skin elasticity and hydration through estrogenic effects.

Common Side Effects: - Local skin irritation or burning sensation. - Mild itching or pruritus. - Dryness or peeling of the applied area. - Transient erythema. - Hyperpigmentation at the site. - Folliculitis or mild acneiform eruption.

Serious or Rare Side Effects: - Allergic contact dermatitis with swelling and vesiculation. - Severe skin atrophy or thinning. - Systemic estrogenic effects such as thromboembolic events. - Adrenal suppression with prolonged use. - Cushingoid appearance or systemic corticosteroid toxicity. - Secondary bacterial or fungal infection of the treated skin.

Before using Linoladiol-H N, consider the following precautions: - Pregnancy: avoid use unless the prescriber determines benefits outweigh potential risks. - Breastfeeding: not recommended due to possible transfer of active ingredients. - Known hypersensitivity: discontinue immediately if allergic reaction occurs. - Infected or broken skin: do not apply on areas with active infection or open wounds. - Hormone‑sensitive conditions: use with caution in patients with a history of estrogen‑dependent tumors. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linoladiol-H N may interact with other medicines as follows:

Major Interactions (Avoid): - Oral systemic estrogen therapy: increased risk of thromboembolic events. - Systemic corticosteroids: additive immunosuppression and adrenal suppression. - Antifungal azoles (e.g., ketoconazole): may raise local corticosteroid concentrations.

Moderate Interactions (Monitor Closely): - CYP450 enzyme inducers (e.g., rifampicin): may reduce corticosteroid efficacy. - Hormonal contraceptives: possible reduction in contraceptive effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) applied nearby: may increase local skin irritation.